Current Report Filing (8-k)
April 24 2020 - 4:06PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, DC
20549
FORM
8-K
CURRENT
REPORT
PURSUANT TO
SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
April 20,
2020
Date of report
(date of earliest event reported)
MusclePharm
Corporation
(Exact name of
registrant as specified in its charter)
Nevada
|
|
000-53166
|
|
77-0664193
|
(State or other
jurisdictions of incorporation or organization)
|
|
(Commission File
Number)
|
|
(I.R.S. Employer
Identification No.)
|
4400 Vanowen Street, Burbank, CA 91505
(Address
of principal executive offices) (Zip Code)
(800) 292-3909
(Registrant’s
telephone number, including area code)
Check the appropriate box below if
the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrants under any of the following
provisions:
☐
Written communications pursuant to
Rule 425 under the Securities Act (17 CFR
230.425)
☐
Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
☐
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Securities registered pursuant to
Section 12(b) of the Act:
Title of each
class
|
Trading
Symbol(s)
|
Name of each exchange on which
registered
|
N/A
|
|
|
Indicate by check mark whether the
registrant is an emerging growth company as defined in Rule 405 of
the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of
this chapter).
Emerging growth company
☐
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the
extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a)
of the Exchange Act. ☐
Item
5.02
Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
Effective as of April 20, 2020, Mr.
Allen Sciarillo was appointed as the Chief Financial Officer of
MusclePharm Corporation (the
“Company”).
Mr. Sciarillo, age 55, joined the
Company on December 16, 2019 as Vice President, Finance. Before
joining the Company, Mr. Sciarillo served as Director of Finance of
The Crypto Company, a public company in the blockchain sector, from
July 2018 to December 2019. Before that, he served as Regional
Chief Financial Officer of Electro Rent Corporation, a provider of
rental, leasing and sales of electronic test and measurement
equipment, from February 2015 to March 2018. He previously served
as Controller of Electro Rent from April 2006 to February 2015. Mr.
Sciarillo earned his Bachelor of Science in Accounting from
California State University, Northridge.
Mr. Sciarillo does not have a
family relationship with any director or executive officer of the
Company or person nominated or chosen by the Company to become a
director or executive officer, and there are no arrangements or
understandings between Mr. Sciarillo and any other person pursuant
to which Mr. Sciarillo was selected to serve as Chief Financial
Officer of the Company. There have been no transactions involving
Mr. Sciarillo that would require disclosure under Item 404(a) of
Regulation S-K under the Securities Exchange Act of 1934, as
amended (the “Exchange Act”). In connection with his
appointment, it is expected that Mr. Sciarillo will enter into the
Company’s standard form of indemnification agreement, the
form of which has been filed as Exhibit 10.1 to the Company’s
Current Report on Form 8-K, filed with the Securities and Exchange
Commission on August 27, 2012.
The Company expects that it will enter into an employment
agreement with Mr. Sciarillo. The Company will file an amendment to
this Form 8-K disclosing the terms of any such employment
agreement within four business days after it has been
finalized.
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
MUSCLEPHARM
CORPORATION
|
|
|
|
|
|
Date:
April 24, 2020
|
By:
|
/s/ Ryan
Drexler
|
|
|
|
Name:
Ryan DrexlerTitle: Chief Executive
Officer
|
|
|
|
|
|